Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(66.7%)
Phase 3
2(33.3%)
6Total
N/A(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT03896685Phase 3Completed

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

Role: collaborator

NCT02754765Phase 3Completed

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Role: collaborator

NCT03827811Unknown

Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis

Role: collaborator

NCT03259269Completed

Expand New Drugs for TB [endTB]

Role: collaborator

NCT03355989Not ApplicableCompleted

Evaluation of Conditional Cash Transfers (CCTs) for Immunization

Role: lead

NCT03310762Not ApplicableCompleted

Immunization Reminder Bracelets Study

Role: lead

NCT03379467Not ApplicableCompleted

Use of SMS and Interactive Reminders to Improve Timely Immunization Coverage

Role: lead

NCT01690754Not ApplicableCompleted

Evaluating the Effectiveness of Interactive SMS Reminders on TB Treatment Outcomes

Role: lead

All 8 trials loaded